Inflammation and thrombosis in cardiovascular disease

Current Opinion in Hematology

Volumn 20, Issue 5, 2013, Pages 457-463

  Nagareddy, Prabhakara ^a   Smyth, Susan S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

cardiovascular disease; inflammation; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; CANAKINUMAB; ETANERCEPT; METHOTREXATE; PEXELIZUMAB; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ACUTE LUNG INJURY; CARDIOVASCULAR INFLAMMATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTOSIS; LOW DRUG DOSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; NEUTROPHILS; THROMBOSIS;

EID: 84883263674     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328364219d     Document Type: Review

References (63)

1. Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Throm Haemost 2009; 7:1759-1766.
2. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2013; 368:1260.
3. Duerschmied D, Suidan GL, Demers M, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121:1008-1015.
4. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139:1143-1156.
5. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119:5972-5979.
6. Shi G, Field DJ, Long X, et al. Platelet factor 4 mediates vascular smooth muscle cell injury responses. Blood 2013; 121:4417-4427.
7. Michelson AD. Platelets. 3rd edn. China: Elsevier; 2013.
8. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104:1533-1537.
9. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38:1002-1006.
10. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-ST elevation acute coronary syndromes. Clin Cardiol 2007; 30:26-31.
11. Ray MJ, Walters DL, Bett JN, et al. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by abciximab. Int J Cardiol 2005; 101:249-255.
12. Evangelista V, Manarini S, Dell'Elba G, et al. Clopidogrel inhibits plateletleukocyte adhesion and platelet dependent leukocyte activation. Throm Haemost 2005; 94:568-577.
13. Totani L, Dell'Elba G, Martelli N, et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Throm Haemost 2012; 107:1130-1140.
14. Graff J, Harder S, Wahl O, et al. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther 2005; 78:468-476.
15. Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L): subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12:74-82.
16. Klinkhardt U, Bauersachs R, Adams J, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease[ast]. Clin Pharmacol Ther 2003; 73:232-241.
17. Steinhubl SR, Badimon JJ, Bhatt DL, et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12:113-122.
18. Antonino MJ, Mahla E, Bliden KP, et al. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009; 103:1546-1550.
19. Tardif JC, Tanguay JF, Wright SS, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECTACS trial. J Am Coll Cardiol 2013; 61:2048-2055.
20. Arakawa K, Yasuda S, Hao H, et al. Significant association between neutrophil aggregation in aspirated thrombus and myocardial damage in patients with ST-segment elevation acute myocardial infarction. Circ J 2009; 73:139-144.
21. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328:1689-1693.
22. Tall AR, Yvan-Charvet L, Westerterp M, Murphy AJ. Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis. Arterioscler Thromb Vasc Biol 2012; 32:2547-2552.
23. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012; 11:195-206.
24. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metabolism 2013; 17:695-708.
25. Borissoff JI, Otten JJ, Heeneman S, et al. Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophildependent manner. PloS One 2013; 8:e55784.
26. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16:887-896.
27. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Throm Vasc Biol 2012; 32:1777-1783.
28. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209:819-835.
29. Darbousset R, Thomas GM, Mezouar S, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012; 120:2133-2143.
30. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Throm Haemost 2012; 10:136-144.
31. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118:1952-1961.
32. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012; 122:2661-2671.
33. de Boer OJ, Li X, Teeling P, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Throm Haemost 2013; 109:290-297.
34. Knight JS, Zhao W, Luo W, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest 2013; 123:2981-2993.
35. Martinod K, Demers M, Fuchs TA, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A 2013; 110:8674-8679.
36. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation 2003; 108:1184-1190.
37. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti- C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108:1176-1183.
38. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009; 301:1779-1789.
39. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
40. Glynn RJ, Danielson E, Fonseca FA, et al.Arandomized trial of rosuvastatin in the prevention of venous thromboembolism.NEngl JMed 2009; 360:1851-1861.
41. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162:597-605.
42. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Throm Haemost 2009; 7 (Suppl 1):332-339.
43. Pieringer H, Pichler M, Pohanka E, Hoppe UC. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis? Curr Pharm Des 2013. [Epub ahead of print]
44. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10:R30.
45. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602.
46. Padfield GJ, Din JN, Koushiappi E, et al. Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: a first in human study. Heart 2013. [Epub ahead of print]
47. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
48. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064.
49. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869-1878.
50. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012; 130:e129-e133.
51. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-247.
52. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Throm Res 2013; 131:383-389.
53. Zhang G, Han J, Welch EJ, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009; 182:7997-8004.
54. Aslam R, Speck ER, Kim M, et al. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107:637-641.
55. Cognasse F, Hamzeh H, Chavarin P, et al. Evidence of toll-like receptor molecules on human platelets. Immunol Cell Biol 2005; 83:196-198.
56. Weyrich AS, Zimmerman GA. Platelets in lung biology. Annu Rev Physiol 2013; 75:569-591.
57. Winning J, Reichel J, Eisenhut Y, et al. Antiplatelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20:50-57.
58. Winning J, Neumann J, Kohl M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010; 38:32-37.
59. Erlich JM, Talmor DS, Cartin-Ceba R, et al. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 2011; 139:289-295.
60. Gross AK, Dunn SP, Feola DJ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and metaanalysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013; 35:147-154.
61. O'Neal HR Jr, Koyama T, Koehler EA, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011; 39:1343-1350.
62. Kor DJ, Erlich J, Gong MN, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011; 39:2393-2400.
63. Kor DJ, Talmor DS, Banner-Goodspeed VM, et al. Lung injury prevention with aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open 2012; 2: e001606; 2.